Recent developments in gene therapy for cardiac disease

Biomedicine and Pharmacotherapy

Volumn 54, Issue 10, 2000, Pages 487-504

  Wattanapitayakul, S K ^a   Bauer, J A ^b  

^a SRINAKHARINWIROT UNIVERSITY   (Thailand)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Adrenergic receptors; Cardiovascular disease; Gene therapy; Gene transfer; Growth factors; Vectors

Indexed keywords

VIRUS VECTOR;

ARTICLE; CARDIOVASCULAR DISEASE; CLONING VECTOR; GENE TARGETING; GENE THERAPY; GENE TRANSFER; HUMAN; PRIORITY JOURNAL; TREATMENT INDICATION;

EID: 0033695103     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0753-3322(00)00014-7     Document Type: Article

References (140)

1. Prevalence and mortality rate of congestive heart failure in the United States
2. Changes in hypertension treatment and in congestive heart failure mortality in the United States
3. The human genome project: Benefits and risks to society
4. Optimal techniques for arterial gene transfer
5. Retroviral vectors: First-generation systems for gene therapy
6. Latest developments in gene transfer technology: Achievements, perspectives, and controversies over therapeutic applications
7. The advent of adenovirus: Gene therapy for cardiovascular disease
8. Adenovirus-mediated gene transfer into rat cardiac allografts
9. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses
10. Adeno-associated virus site-specifically integrates into muscle-specific DNA region
11. Is gene therapy for hypertension possible?
12. A high-titer lentiviral production system mediates efficient transduction of differentiated cells including beating cardiac myocytes
13. Multiple vectors effectively achieve gene transfer in a murine cardiac transplantation model
14. Introduction
15. A DNA controlled-release coating for gene transfer: Transfection in skeletal and cardiac muscle
16. In vivo transfection of cis element 'decoy' against NFχB binding site prevented myocardial infarction as gene therapy
17. Gene therapy using HVJ-liposomes: The best of both?
18. Quantitative determination of adenovirus-mediated gene delivery to rat cardiac myocytes in vitro and in vivo
19. Gene therapy using HVJ-liposomes: The best of both worlds?
20. Antisense inhibition of β1-adrenergic receptor mRNA in a single dose produces a profound and prolonged reduction in high blood pressure in spontaneously hypertensive rats
21. Potential future therapies for heart failure: Gene transfer of β-adrenergic signaling components
22. Beta-adrenoceptors in cardiac disease
23. β1 and β2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: Coupling of both receptor subtypes to muscle contraction and selective β1-receptor down-regulation in heart failure
24. New insight into the role of enhanced adrenergic receptor-effector coupling in the heart
25. Expression of β-arrestins and β-adrenergic receptor kinases in the failing human heart
26. Preliminary characterization of a transgenic mouse overexpressing the human β1 adrenergic receptor
27. Echocardiographic and histopathological characterization of young and old transgenic mice overexpressing the human β1-adrenergic receptor
28. Enhanced myocardial function in transgenic mice overexpressing the beta 2-adrenergic receptor
29. Cardiac function in mice overexpressing the β-adrenergic receptor kinase or a βARK inhibitor
30. Adverse effects of chronic endogenous sympathetic drive induced by cardiac Gsα overexpression
31. Reversal of potassium channel deficiency in cells from failing hearts by adenoviral gene transfer: A prototype for gene therapy for disorders of cardiac excitability and contractility
32. Intracellular calcium homeostasis in cardiac myocytes
33. Altered sarcoplasmic reticulum Ca2+-ATPase gene expression in the human ventricle during end-stage heart failure
34. Contribution of abnormal sarcoplasmic reticulum Ca2+ activity to systolic and diastolic dysfunction in human heart failure
35. Simultaneous reduction of the sarcolemmal and SR calcium ATPase activities and gene expression in cardiomyopathic hamster
36. Function of the sarcoplasmic reticulum and expression of its Ca2+ ATPase gene in pressure-overload-induced cardiac hypertrophy in the rat
37. Transition from hypertrophy to failure
38. Long-term angiotensin-converting enzyme inhibition with fosinopril improves depressed responsiveness to Ca2+ in myocytes from aortic-banded rats
39. The sarcoplasmic reticulum Ca2+-ATPase (SERCA2) gene promoter activity is decreased in response to severe left ventricular pressure-overload hypertrophy in rat hearts
40. Adenoviral gene transfer of SERCA2a improves left-ventricular function in aortic-banded rats in transition to heart failure
41. Cell-specific promoter in adenovirus vector for transgenic expression of SERCA1 ATPase in cardiac myocytes
42. Comparison of SERCA1 and SERCA2a expressed in COS-1 cells and cardiac myocytes
43. Prospects for gene therapy for heart failure
44. The renin-angiotensin system and its receptors
45. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection
46. Prevention of renovascular and cardiac pathophysiological changes in hypertension by angiotensin II type 1 receptor antisense gene therapy
47. Permanent cardiovascular protection from hypertension by the AT(1) receptor antisense gene therapy in hypertensive rat offspring
48. Angiotensin I-converting enzyme antisense gene therapy causes permanent antihypertensive effects in the SHR
49. Angiotensin receptors and development: The kidney
50. The effects of antiotensin and specific angiotensin receptor blockers on embryonic cardiac development and looping patterns
51. Chronic antisense therapy for angiotensinogen on cardiac hypertrophy in spontaneously hypertensiye rats
52. Atrial natriuretic peptide gene delivery reduces stroke-induced mortality rate in Dahl salt-sensitive rats
53. Adenovirus-mediated kallikrein gene delivery reduces aortic thickening and stroke-induced death rate in Dahl salt-sensitive rats
54. Molecular genetics of human hypertension
55. Biologic bypass with the use of adenoirus-mediated gene transfer of the complementary deoxyribonucleic acid for vascular endothelial growth factor 121 improves myocardial perfusion and function in the ischemic porcine heart
56. Gene therapy for myocardial angiogenesis: Initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia
57. Angiogenesis gene therapy: Phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease
58. VEGF gene delivery to myocardium: Deleterious effects of unregulated expression
59. Angiogenesis and growth factor expression in a model of transmyocardial revascularization
60. Enhanced angiogenesis and unfavorable remodeling in injured porcine coronary artery lesions: Effects of local basic fibroblast growth factor delivery
61. Histologic evidence that basic fibroblast growth factor enhances the angiogenic effects of transmyocardial laser revascularization
62. The stimulation of neoaniogenesis in the ischemic human heart by the growth factor FGF: First clinical results
63. Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery: Results of a phase I randomized, double-blind, placebo-controlled trial
64. Basic FGF enhances calcium-permeable channel openings in adult rat cardiac myocytes: Implication in the bFGF-induced increase of free Ca2+ content
65. Fibroblast growth factor-2 mediates pressure-induced hypertrophic response
66. Overexpression of long or short FGFR-1 results in FGF-2-mediated proliferation in neonatal cardiac myocyte culture
67. Hepatocyte growth factor and its receptor are expressed in cardiac myocytes during early cardiogenesis
68. Enhanced expression of hepatocyte growth factor/c-Met by myocardial ischemia and reperfusion in a rat model
69. The cytokine heaptocyte growth factor/scatter factor inhibits apoptosis and enhances DNA repair by a common mechanism involving signaling through phospharidyl inositol 3' kinase
70. Potential role of hepatocyte growth factor, a novel angiogenic growth factor, in peripheral arterial disease: Downregulation of HGF in response to hypoxia in vascular cells
71. Gene transfection of hepatocyte growth factor attenuates reperfusion injury in the heart
72. Angiogenesis induced by hepatocyte growth factor in non-infarcted myocardium and infarcted myocardium: Up-regulation of essential transcription factor for angiogenesis, etc.
73. Enhanced secretion of cardiac hepatocyte growth factor from an infarct region is associated with less severe ventricular enlargement and improved cardiac function
74. Targets of oxidative stress in cardiovascular system
75. Oxidative stress during myocardial ischaemia and heart failure
76. Potential new cardiovascular risk factors: Left ventricular hypertrophy, homocysteine, lipoprotein(a), triglycerides, oxidative stress, and fibrinogen
77. Increased oxidative stress in patients with congestive heart failure
78. Superoxide production in vascular smooth muscle contributes to oxidative stress and impaired relaxation in atherosclerosis
79. The protective role of manganese superoxide dismutase against adriamycin-induced acute cardiac toxicity in transgenic mice
80. Suppression of doxorubicin cardiotoxicity by overexpression of catalase in the heart of transgenic mice
81. Recombinant adenovirus-mediated cardiac gene transfer of superoxide dismutase and catalase attenuates postischemic contractile dysfunction
82. Gene therapy with extracellular superoxide dismutase attenuates myocardial stunning in conscious rabbits
83. Modulation of leukocyte-endothelial interactions by reactive metabolites of oxygen and nitrogen: Relevance to ischemic heart disease
84. Nitric oxide synthase in atherosclerosis and vascular injury. Insights from experimental gene therapy
85. Regulation of basal myocardial function by NO
86. Impairment and restoration of nitric oxide-dependent vasodilation in cardiovascular disease
87. Endothelial dysfunction and peroxynitrite formation are early events in angiotensin-induced cardiovascular disorders
88. Oxidative stress during myocardial ischaemia and heart failure
89. Impaired endothelial function in arterial hypertension and hypercholesterolemia: Potential mechanisms and differences
90. Percutaneous gene therapy using recombinant adenoviruses encoding human herpes simplex virus, thymidine kinase, human PAI-1, and human NOS3 in balloon-injured porcine coronary arteries
91. Gene transfer of endothelial nitric oxide synthase improves nitric oxide-dependent endothelial function in a hypertensive rat model
92. Inducible nitric oxide synthase (iNOS) expression upregulates p21 and inhibits vascular smooth muscle cell proliferation through p42/44 mitogen-activated protein kinase activation and independent of p53 and cyclic guanosine monophosphate
93. Cardiovascular gene therapy
94. Optimization of ex vivo pressure mediated delivery of antisense oligodeoxynucleotides to ICAM-1 reduces reperfusion injury in rat cardiac allografts
95. Gene therapy for heart transplantation-associated coronary arterosclerosis
96. Analysis of the upstream regions governing expression of the chicken cardiac troponin T gene in embryonic cardiac and skeletal muscle cells
97. Identification of cis elements in the cardiac troponin T gene conferring specific expression in cardiac muscle of transgenic mice
98. Muscle differentiation during repair of myocardial necrosis in rats via gene transfer with MyoD
99. Myocardium injury-induced fibroblast proliferation facilitates retroviral-mediated gene transfer to the rat heart in vivo
100. Widespread long-term gene transfer to mouse skeletal muscles and heart
101. Expression of recombinant genes in myocardium in vivo after direct injection of DNA
102. Adenovirus-mediated gene transfer into rat cardiac allografts: Comparison of direct injection and perfusion
103. Ultrarapid, highly efficient viral gene transfer to the heart
104. Pressure-mediated oligonucleotide transfection of rat and human cardiovascular tissues
105. Enhanced cardiac contractility after gene transfer of V2 vasopressin receptors in vivo by ultrasound-guided injection or transcoronary delivery
106. Percutaneous adenoviral gene transfer into porcine coronary arteries: Is cartheter-based gene delivery adapted to coronary circulation?
107. Catheter-mediated vascular endothelial growth factor gene transfer to human coronary arteries after agioplasty
108. Exogenous control of cardiac gene therapy: Evidence of regulated myocardial transgene expression after adenovirus and adeno-associated virus transfer of expression cassettes containing corticosteroid response element promoters
109. Preservation of myocardial β-adrenergic receptor signaling delays the development of heart failure after myocardial infarction
110. Highly efficient adenovirus-mediated gene transfer to cardiac myocytes after single-pass coronary delivery
111. Cell transplantation as future therapy for cardiovascular disease?
112. Gene transfer into mouse embryonic stem cell-derived cardiac myocytes medicated by recombinant adenovirus
113. Users' guides to the medical literature. XIII. How to use an article on economic analysis of clinical practice. A. Are the results of the study valid?
114. Statistical issues in cost-effectiveness analysis
115. Expert panel vs decision-analysis recommendations for postdischarge coronary angiography after myocardial infarction
116. Cost-effectiveness analysis in clinical practice
117. A pharmacoeconomic assessment of torsemide and furosemide in the treatment of patients with congestive heart failure
118. Pharmacoeconic aspects of treatment of acute myocardial infarction with thrombolytic agents
119. Prospects for adenovirus-mediated gene therapy of inherited diseases of the myocardium
120. Systemic gene expression after intravenous DNA delivery into adult mice
121. Gene therapy for donor hearts: Ex vivo liposome-mediated transfection
122. Efficient gene transfer into cardiac myocytes using adeno-associated virus (AAV) vectors
123. Direct myocardial transfection in two animal models. Evaluation of parameters affecting gene expression and percutaneous gene delivery
124. Direct in vivo gene transfer into porcine myocardium using replication-deficient adenoviral vectors
125. The route of adminstration is a major determinant of the transduction efficiency of rat tissues by adenoviral recombinants
126. Efficient in vivo gene transfer into the heart in the rat myocardial infarction model using the HVJ (Hemagglutinating Virus of Japan)-liposome method
127. Adenovirus-mediated expression of a voltage-gated potassium channel in vitro (rat cardiac myocytes) and in vivo (rat liver). A novel strategy for modifying excitability
128. Enhancement of murine cardiac chronotropy b the molecular transfer of the human β2 adrenergic receptor cDNA
129. Adenovirus-mediated gene transfer of the β2-adrenergic receptor to donor hearts enhances cardiac function
130. Enhancement of cardiac function after adenoviral-mediated in vivo intracoronary β2-adrenergic receptor gene delivery
131. Restoration of β-adrenergic signaling in failing cardiac ventricular myocytes via adenoviral-mediated gene transfer
132. Complete reversal of ischemic wall motion abnormalities by combined use of gene therapy with transmyocardial laser revascularization
133. Focal angiogen therapy using intramyocardial delivery of an adenovirus viector coding for vascular endothelialgrowth factor 121
134. Overexpression of long or short FGFR-1 results in FGF-2-mediated proliferatin in neonatal cardiac myocyte cultures
135. Intracoronary adenovirus-mediated transfer of immunosuppressive cytokine genes prolongs allograft survival
136. Heart muscle-specific gene expression using replication defective recombinant adenovirus
137. Analysis of tissue-specific gene delivery by recombinant adenoviruses containing cardiac-specific promoters
138. Regulated expression of a foreign gene targeted to the ischaemic myocardium
139. Muscle differentiation during repair of myocardial necrosis in rats via gene transfer with MyoD